Risk of bleeding and thrombosis in patients 70 years or older using Vitamin K antagonists

JAMA Internal Medicine

Volumn 176, Issue 8, 2016, Pages 1176-1183

  Kooistra, Hilde A M ^a,b   Calf, Agneta H ^c   Piersma Wichers, Margriet ^a,b   Kluin Nelemans, Hanneke C ^a   Izaks, Gerbrand J ^a   Veeger, Nic J G M ^a   Meijer, Karina ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b Thrombosis Service Groningen   (Netherlands)

^c MEDICAL CENTER LEEUWARDEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVITAMIN K; ANTICOAGULANT AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; VITAMIN K GROUP;

AGE; AGED; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; CHRONIC PATIENT; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG INDICATION; EPISTAXIS; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; GERIATRIC PATIENT; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SKIN BLEEDING; THROMBOSIS; TREATMENT DURATION; URINARY TRACT HEMORRHAGE; VERY ELDERLY; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; PROPORTIONAL HAZARDS MODEL; VENOUS THROMBOEMBOLISM;

AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICOAGULANTS; COHORT STUDIES; FEMALE; HEMORRHAGE; HUMANS; MALE; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; VENOUS THROMBOEMBOLISM; VITAMIN K;

EID: 84980322306     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2016.3057     Document Type: Article

References (21)

1. Hutten BA, Prins MH. Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism. Cochrane Database Syst Rev. 2006;(1): CD001367.
2. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857-867.
3. Fihn SD, Callahan CM, Martin DC, McDonell MB, Henikoff JG, White RH; The National Consortium of Anticoagulation Clinics. The risk for and severity of bleeding complications in elderly patients treated with warfarin. Ann Intern Med. 1996;124(11): 970-979.
4. Palareti G, Leali N, Coccheri S, et al; Italian Study on Complications of Oral Anticoagulant Therapy. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Lancet. 1996;348 (9025):423-428.
5. Poli D, Antonucci E, Testa S, Tosetto A, Ageno W, Palareti G; Italian Federation of Anticoagulation Clinics. Bleeding risk in very old patients on vitamin K antagonist treatment: results of a prospective collaborative study on elderly patients followed by Italian Centres for Anticoagulation. Circulation. 2011;124(7):824-829.
6. Razouki Z, Ozonoff A, Zhao S, Jasuja GK, Rose AJ. Improving quality measurement for anticoagulation: adding international normalized ratio variability to percent time in therapeutic range. Circ Cardiovasc Qual Outcomes. 2014;7(5): 664-669.
7. van Leeuwen Y, Rosendaal FR, Cannegieter SC. Prediction of hemorrhagic and thrombotic events in patients with mechanical heart valve prostheses treated with oral anticoagulants. J Thromb Haemost. 2008;6(3):451-456.
8. Veeger NJ, Piersma-Wichers M, Tijssen JG, Hillege HL, van der Meer J. Individual time within target range in patients treated with vitamin K antagonists: main determinant of quality of anticoagulation and predictor of clinical outcome: a retrospective study of 2300 consecutive patients with venous thromboembolism. Br J Haematol. 2005;128(4):513-519.
9. Palareti G, Cosmi B. Bleeding with anticoagulation therapy-who is at risk, and how best to identify such patients. Thromb Haemost. 2009;102(2):268-278.
10. Cohen N, Almoznino-Sarafian D, Alon I, et al. Warfarin for stroke prevention still underused in atrial fibrillation: patterns of omission. Stroke. 2000;31(6):1217-1222.
11. Hylek EM, D'Antonio J, Evans-Molina C, Shea C, Henault LE, Regan S. Translating the results of randomized trials into clinical practice: the challenge of warfarin candidacy among hospitalized elderly patients with atrial fibrillation. Stroke. 2006;37(4):1075-1080.
12. Rothwell PM, Coull AJ, Giles MF, et al; Oxford Vascular Study. Change in stroke incidence, mortality, case-fatality, severity, and risk factors in Oxfordshire, UK from 1981 to 2004 (Oxford Vascular Study). Lancet. 2004;363(9425): 1925-1933.
13. López-Jiménez L, Montero M, González-Fajardo JA, et al; RIETE Investigators. Venous thromboembolism in very elderly patients: findings from a prospective registry (RIETE). Haematologica. 2006;91(8):1046-1051.
14. Mant J, Hobbs FD, Fletcher K, et al; BAFTA investigators; Midland Research Practices Network (MidReC). Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet. 2007;370 (9586):493-503.
15. Erkens PM, ten Cate H, Büller HR, Prins MH. Benchmark for time in therapeutic range in venous thromboembolism: a systematic review and meta-analysis. PLoS One. 2012;7(9):e42269. doi:10.1371/journal.pone.0042269.
16. Bezemer ID, Roemer WH, Penning-van Beest FJ, van Eekelen E, Kramer MH. INR control calculation: comparison of Dutch and international methods. Neth J Med. 2013;71(4):194-198.
17. Schulman S, Kearon C; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692-694.
18. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briët E. Amethod to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993;69(3):236-239.
19. Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation. 2007;115 (21):2689-2696.
20. Poli D, Antonucci E, Testa S, Cosmi B, Palareti G, Ageno W; FCSA Italian Federation of Anticoagulation Clinics. The predictive ability of bleeding risk stratification models in very old patients on vitamin K antagonist treatment for venous thromboembolism: results of the prospective collaborative EPICA study. J Thromb Haemost. 2013;11(6):1053-1058.
21. Veeger NJ, Piersma-Wichers M, Meijer K, Hillege HL. Minor bleeds alert for subsequent major bleeding in patients using vitamin K antagonists. Br J Haematol. 2011;153(4):508-514.